# Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

> **NCT01466179** · PHASE2 · COMPLETED · sponsor: **Amgen Research (Munich) GmbH** · enrollment: 225 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Blinatumomab

## Key facts

- **NCT ID:** NCT01466179
- **Lead sponsor:** Amgen Research (Munich) GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-10
- **Final completion:** 2017-01
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01466179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01466179, "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01466179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*